This inventor holds 1 USPTO granted patent. Top assignee: Tianjin University. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Peihua Liang: Innovator in Etoricoxib Solvates
Introduction
Peihua Liang is a notable inventor based in Tianjin, China, recognized for his contributions in the field of pharmacology, specifically concerning etoricoxib solvates. His innovative work centers on enhancing the solubility and stability of etoricoxib, a nonsteroidal anti-inflammatory drug (NSAID), through novel preparation methods.
Latest Patents
Liang holds a significant patent titled "Etoricoxib solvates and preparation method thereof." This patent discloses a method of creating solvates of etoricoxib using specific hydrogen bond donor solvents and hydrogen bond acceptor solvents with precise polarity values. The resultant etoricoxib solvates demonstrate high thermal stability, unique crystal forms, and a concentrated distribution that contributes to their enhanced flowability. These solvates are highlighted for their safety and efficiency, with preparation processes exhibiting a molar yield higher than 90%.
Career Highlights
Currently, Peihua Liang is affiliated with Tianjin University, where he applies his expertise in chemistry and pharmacology to advance research in drug formulations. His innovative methods contribute not only to scientific knowledge but also to practical applications in medicine, facilitating improved therapeutic outcomes for patients.
Collaborations
Liang collaborates with esteemed colleagues in his field, including Ying Bao and Feng Zhang. Their combined efforts foster a productive research environment, leading to breakthroughs in drug formulations and enhancing the effectiveness of pharmacological treatments.
Conclusion
Peihua Liang's contributions to the field of etoricoxib solvates showcase the impact of innovative thinking in pharmaceutical sciences. His patent not only addresses critical challenges in drug solubility and stability but also sets a precedent for future research and development in medicinal chemistry. As Liang continues his work at Tianjin University, the medical community eagerly anticipates further advancements stemming from his valuable research initiatives.